Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Jackman DM et al. – EGFR mutation status is associated with sensitivity to treatment with an EGFR–TKI in patients with advanced non–small cell lung cancer. Patients harboring sensitizing EGFR mutations should be considered for first–line erlotinib or gefitinib.

Related Articles

Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)
British Journal of Cancer, 11/30/09    Relevance Score: 70%

Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial
BJU International, 11/25/09    Relevance Score: 70%

Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor
Oncogene, 11/19/09    Relevance Score: 70%

Pathophysiologic Correlation Between 62Cu-ATSM and 18F-FDG in Lung Cancer
The Journal of Nuclear Medicine, 11/17/09    Relevance Score: 70%

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
Journal of Clinical Oncology, 11/12/09    Relevance Score: 70%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address